CD70-directed modalities exhibit distinct profiles: mAbs block CD70/CD27 interactions with low cytokine release syndrome risk but poor tumor penetration; ADCs deliver potent toxins yet face thrombocytopenia; CAR-Ts achieve durable responses despite fratricide and tumor microenvironment (TME) suppression; CAR-NKs offer GVHD-free, off-the-shelf therapy with stromal targeting but limited expansion. Here, CD70 is linked to neoplasm.